With the FDA approval of Zenbexus this summer, Bristol Myers Squibb checked off two notable ‘firsts,’ scoring the inaugural ...
Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...
Just shy of two months after teeing up its FcRn blocker Vyvgart Hytrulo for entry into another potential immunology niche, ...
Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
As the Trump administration advances plans to bring its “most favored nation” drug pricing model to Medicare Part B, the ...
London-based women’s health pharma Theramex has agreed to pay up to $250 million to license Shanghai-based Asieris’ first-in-class non-surgical treatment for cervical precancerous lesions associated ...
The people and organizations advancing what's possible in health, science and patient care. Ayla Ellison Sep 1, 2026 5:00am ...
A U.K. drug marketing watchdog has slammed CSL Seqirus for “multiple and prolonged deficiencies” in its systems, governance ...
A little over a year after landing its flagship approval in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is expanding ...
After facing a setback in Germany late last year, Merck & Co.’s European marketing plans for its below-the-skin Keytruda SC are growing more complicated. | After facing a setback in Germany late last ...
The National Fragility Index, launched by the API Innovation Center, warns that more than 550 million prescriptions filled in the U.S. in 2023 were for drugs ranked as having high or severe ...
The successes of the GLP-1 class for chronic weight management “introduced consumer overlay over a historically physician-driven therapeutic area,” Pothier explained, noting that despite the potency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results